The vaccine protects against the serotypes responsible for the majority of adult invasive pneumococcal disease ...

Dominance of the pneumococcal vaccine category is a race between Merck & Co and Pfizer, and while the latter is comfortably in front at the moment with its Prevnar franchise, Merck has multiple ...

Merck already sells an older pneumococcal vaccine called Pneumovax 23, which protects against 23 strains but is a polysaccharide based shot, so doesn't stimulate as strong an immune response as ...

Merck (MRK), known as MSD outside of the United States and Canada, announced that the European Commission, or EC, has approved CAPVAXIVE, or Pneumococcal 21-valent Conjugate Vaccine, for active ...

Merck MRK announced that the European Commission (“EC”) has approved its 21-valent pneumococcal conjugate vaccine (“PCV”), Capvaxive, for the prevention of invasive pneumococcal disease ...

Merck's Capvaxive gears up to challenge ... Elizabeth Banks stars in Pfizer's new pneumococcal vaccine awareness push. (Pfizer) “It’s up to us to lead the charge,” she says in a video ...

Merck’s new 21-valent pneumococcal conjugate vaccine, Capvaxive, and Winrevair have the potential to generate significant revenues for Merck over the long term. Both the products are witnessing ...

Pneumococcal pneumonia is a potentially serious bacterial lung disease that can disrupt your life for weeks and even land you in the hospital. Medical experts want you to know that there are steps you ...

Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays ...